Nurix Therapeutics partners with Roche on BTK degrader drug deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'
June 8, 2026 10:48 AM EDTOppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix announced a global collaboration with Roche to co-develop and co-commercialize bex-deg, and in our view this is the outcome investors were hoping... More
